Shanghai Pharmaceuticals Holding Co., Ltd
601607
Rankning i aktier
#2386
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding... Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
Aktiekurs
$2.43
Marknadsvärde
$8.09B
Förändring (1 dag)
-1.16%
Förändring (1 år)
-5.94%
Land
CN
Handel Shanghai Pharmaceuticals Holding Co., Ltd (601607)
Kategori
Healthcare
P/E-tal för Shanghai Pharmaceuticals Holding Co., Ltd (601607)
P/E-tal per October 2026 TTM: 12.56
Enligt Shanghai Pharmaceuticals Holding Co., Ltd senaste finansiella rapporter och aktiekurs är det aktuella P/E-talet (TTM) 12.56. I slutet av 2024 hade företaget ett P/E-tal på 17.09.
Historik för P/E-tal för Shanghai Pharmaceuticals Holding Co., Ltd från 2001 till 2026
P/E-tal vid slutet av varje år
| År | P/E-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 12.56 | 8.26% |
| 2025 | 11.60 | -32.13% |
| 2024 | 17.09 | 4.19% |
| 2023 | 16.40 | 48.37% |
| 2022 | 11.05 | -0.29% |
| 2021 | 11.09 | -8.65% |
| 2020 | 12.14 | -5.13% |
| 2019 | 12.79 | 7.07% |
| 2018 | 11.95 | -35.65% |
| 2017 | 18.57 | 12.84% |
| 2016 | 16.45 | -11.57% |
| 2015 | 18.61 | 8.74% |
| 2014 | 17.11 | -4.75% |
| 2013 | 17.97 | 23.58% |
| 2012 | 14.54 | 10.80% |
| 2011 | 13.12 | -58.75% |
| 2010 | 31.81 | -80.24% |
| 2009 | 160.94 | 221.88% |
| 2008 | 50.00 | -59.78% |
| 2007 | 124.31 | 208.48% |
| 2006 | 40.30 | 28.12% |
| 2005 | 31.45 | 47.65% |
| 2004 | 21.30 | 15.77% |
| 2003 | 18.40 | -31.84% |
| 2002 | 27.00 | 12.69% |
| 2001 | 23.96 | 0.00% |
P/E-tal för liknande företag eller konkurrenter
| Företag | P/E-tal | Skillnad i P/E-tal | Land |
|---|---|---|---|
| 26.02 | 107.20% |
US
|
|
| - | - |
US
|
|
| 34.08 | 171.35% |
US
|
|
| - | - |
US
|
|
| 45.62 | 263.25% |
AU
|
Hur man läser ett P/E-tal
P/E-talet (Price/Earnings) mäter förhållandet mellan ett företags aktiekurs och dess vinst per aktie.
Ett lågt men positivt P/E visar ett företag med hög vinst i förhållande till värderingen och kan vara undervärderat. Ett högt negativt (nära 0) P/E indikerar stora förluster.
Företag med P/E över 30 eller negativt ses ofta som "tillväxtaktier", vilket innebär att investerare förväntar sig tillväxt eller framtida lönsamhet.
Företag med positivt P/E under 10 ses som "värdeaktier" och är redan lönsamma men med begränsad tillväxtpotential.